Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artificial Tears for Radioiodine Levels in Thyroid Carcinoma Patients
NCT04327999Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Oct 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of artificial tears + corticosteroid drops in nasolacrimal duct obstruction (NLDO), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Change in Level of Radioactive Iodine in Tears at 4 days. Started Oct 2020; status: terminated.
02
Drugs
artificial tears + corticosteroid drops
03
Conditions
nasolacrimal duct obstruction (NLDO)
Beyond the preview
Go deeper on NCT04327999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04327999.